94:(HCC); it was present in 91% of HCC patients, while not being detectable in other liver diseases. The DCP level did not change with the administration of vitamin K, suggesting a defect in gamma-carboxylation activity rather than vitamin K deficiency. A number of subsequent studies have since confirmed this phenomenon.
351:
Ertle, JM; Heider, D; Wichert, M; Keller, B; Kueper, R; Hilgard, P; Gerken, G; Schlaak, JF (2013). "A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma".
289:
Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA (2007). "Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3".
105:), and hence the most useful in predicting HCC. It differentiates HCC from non-malignant liver diseases. Moreover, it has been demonstrated that a combined analysis of DCP and
218:
Cui R, Wang B, Ding H, Shen H, Li Y, Chen X (2002). "Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma".
324:
Lamerz R, Runge M, Stieber P, Meissner E (1999). "Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases".
144:
Liebman HA, Furie BC, Tong MJ, et al. (1984). "Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma".
250:"Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients"
116:, only did a 2003 American study reevaluate its use in an American patient series. It also identified HCC at an earlier stage.
43:
441:
54:
91:
446:
389:"Use of des-gamma-carboxyprothrombin in retrospective diagnosis of hidden intoxication of anticoagulants"
418:
369:
333:
306:
271:
227:
200:
183:(1990). "Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma".
161:
106:
408:
400:
361:
298:
261:
192:
153:
124:
A 1987 report described the use of DCP determination in the detection of intoxication with
180:
50:
413:
388:
435:
125:
70:
46:
98:
62:
157:
39:
35:
266:
249:
102:
66:
404:
373:
337:
310:
275:
231:
196:
422:
302:
204:
165:
74:
17:
365:
113:
58:
101:
found DCP the least sensitive to risk factors for HCC (such as
109:(AFP) can lead to a better prediction in early stages of HCC.
65:. DCP/PIVKA-II may be detected in people with deficiency of
90:
A 1984 study first described the use of DCP as a marker of
77:
or other medication that inhibits the action of vitamin K.
32:protein induced by vitamin K absence/antagonist-II
42:. Normally, the prothrombin precursor undergoes
248:Marrero JA, Su GL, Wei W, et al. (2003).
179:Tsai SL, Huang GT, Yang PM, Sheu JC, Sung JL,
8:
412:
265:
243:
241:
136:
34:(PIVKA-II), is an abnormal form of the
7:
28:Des-gamma carboxyprothrombin (DCP)
25:
97:A 2007 comparison of various HCC
1:
112:Despite many years of use in
387:Lefrere JJ, Gozin D (1987).
158:10.1056/NEJM198405313102204
463:
128:, a vitamin K antagonist.
120:Anticoagulant intoxication
69:(due to poor nutrition or
55:gamma-glutamyl carboxylase
92:hepatocellular carcinoma
86:Hepatocellular carcinoma
61:prior to secretion into
267:10.1053/jhep.2003.50195
405:10.1136/jcp.40.5.589-b
197:10.1002/hep.1840110321
73:) and in those taking
303:10.3233/cbm-2007-3202
442:Coagulation system
44:post-translational
366:10.1159/000346080
107:Alpha-fetoprotein
16:(Redirected from
454:
427:
426:
416:
384:
378:
377:
348:
342:
341:
321:
315:
314:
286:
280:
279:
269:
245:
236:
235:
215:
209:
208:
176:
170:
169:
141:
30:, also known as
21:
462:
461:
457:
456:
455:
453:
452:
451:
432:
431:
430:
393:J. Clin. Pathol
386:
385:
381:
350:
349:
345:
332:(4A): 2489–93.
323:
322:
318:
288:
287:
283:
247:
246:
239:
217:
216:
212:
178:
177:
173:
152:(22): 1427–31.
146:N. Engl. J. Med
143:
142:
138:
134:
122:
88:
83:
51:carboxylic acid
49:(addition of a
23:
22:
15:
12:
11:
5:
460:
458:
450:
449:
444:
434:
433:
429:
428:
379:
343:
326:Anticancer Res
316:
291:Cancer Biomark
281:
260:(5): 1114–21.
237:
210:
171:
135:
133:
130:
121:
118:
87:
84:
82:
81:Diagnostic use
79:
24:
14:
13:
10:
9:
6:
4:
3:
2:
459:
448:
447:Tumor markers
445:
443:
440:
439:
437:
424:
420:
415:
410:
406:
402:
398:
394:
390:
383:
380:
375:
371:
367:
363:
360:(2): 121–31.
359:
355:
347:
344:
339:
335:
331:
327:
320:
317:
312:
308:
304:
300:
296:
292:
285:
282:
277:
273:
268:
263:
259:
255:
251:
244:
242:
238:
233:
229:
225:
221:
214:
211:
206:
202:
198:
194:
190:
186:
182:
175:
172:
167:
163:
159:
155:
151:
147:
140:
137:
131:
129:
127:
126:acenocoumarol
119:
117:
115:
110:
108:
104:
100:
99:tumor markers
95:
93:
85:
80:
78:
76:
72:
71:malabsorption
68:
64:
60:
56:
52:
48:
47:carboxylation
45:
41:
37:
33:
29:
19:
396:
392:
382:
357:
353:
346:
329:
325:
319:
297:(2): 79–87.
294:
290:
284:
257:
253:
223:
220:Chin. Med. J
219:
213:
191:(3): 481–8.
188:
184:
174:
149:
145:
139:
123:
111:
96:
89:
31:
27:
26:
226:(1): 42–5.
40:prothrombin
36:coagulation
436:Categories
399:(5): 589.
254:Hepatology
185:Hepatology
132:References
53:group) by
354:Digestion
103:cirrhosis
67:vitamin K
38:protein,
374:23406785
338:10470180
311:17522429
276:12717392
232:11930656
75:warfarin
18:PIVKA-II
423:3584512
414:1141034
205:2155866
181:Chen DS
166:6201741
57:in the
421:
411:
372:
336:
309:
274:
230:
203:
164:
63:plasma
114:Japan
59:liver
419:PMID
370:PMID
334:PMID
307:PMID
272:PMID
228:PMID
201:PMID
162:PMID
409:PMC
401:doi
362:doi
299:doi
262:doi
224:115
193:doi
154:doi
150:310
438::
417:.
407:.
397:40
395:.
391:.
368:.
358:87
356:.
330:19
328:.
305:.
293:.
270:.
258:37
256:.
252:.
240:^
222:.
199:.
189:11
187:.
160:.
148:.
425:.
403::
376:.
364::
340:.
313:.
301::
295:3
278:.
264::
234:.
207:.
195::
168:.
156::
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.